News
AI Pharma: 2 Paths to AI-Powered Drug Investment
The pharmaceutical industry is on the verge of a significant transformation due to the emergence of artificial intelligence (AI). Traditionally, drug development has been a lengthy, costly, and
EQS-News: BB Biotech: Vorläufige Jahresergebnisse 2024 und Dividendenvorschlag
EQS-Adhoc: BB Biotech AG mit Gewinn im Geschäftsjahr 2024
Sonova präsentiert auf der J.P. Morgan 2025 Healthcare Conference
Sonova gibt personelle Veränderungen im Verwaltungsrat bekannt
Why Novartis Stock Topped the Market Today
Although it's never guaranteed that regulatory approval of a new drug will juice the share price of its developer, this often happens in the pharmaceutical field. Sure enough, after receiving
Why Roche Holding Stock Popped Today
Roche Holding (OTC: RHHBY) stock jumped 3.4% through 1:05 p.m. ET Monday after the pharmaceutical giant's Genentech subsidiary announced positive phase 3 clinical trial results for its fenebrutinib
AEVIS VICTORIA SA (AEVS.SW) – Continued revenue growth in the third quarter of 2025
Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think)
Shares in Avidity Biosciences (NASDAQ: RNA) soared by 42% in the week to Friday morning following the announcement of a unanimous deal for Avidity to be acquired by Novartis (NYSE: NVS) for $72 per
Why Dyne Therapeutics Stock Crushed the Market on Monday
Dyne Therapeutics (NASDAQ: DYN) had a Monday neither it nor its investors will ever forget. This wasn't of its own making, however, as a premium-priced buyout of a peer was attracting serious
Why Avidity Biosciences Stock Blasted 42% Higher Today
A richly priced buyout seriously boosted the share price of biotech Avidity Biosciences (NASDAQ: RNA) as the stock trading week began. The company's equity rose by 42%, closing to land just below
Watch Out Eli Lilly, This Pharma Giant Is Gunning to Be a Top Player in the Obesity Market
Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of more than $760 billion. It has been soaring in recent years due to the success of its highly
2 Surefire Dividend Stocks to Buy for the Long Haul
Equity markets experienced significant volatility this year. Many investors feared that President Donald Trump's aggressive trade policies would plunge the economy into a recession and lead to a
AEVIS VICTORIA SA – Strong growth in revenue in the first half of 2025. Free cash flow exceeds CHF 100 million, enabling debt reduction of more than CHF 120 million.
AEVIS VICTORIA SA – Strong growth in revenue and consolidated results in the first half of 2025
Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal
Shares in Arrowhead Pharmaceuticals (NASDAQ: ARWR) rose by more than 27% in the week to Friday morning. The company's bold aim is to have "20 individual products, either partnered or wholly owned
AEVIS VICTORIA SA (AEVS.SW) – Swiss Medical Network – Revenue increased by more than 20% in the first half of 2025 despite challenging conditions
Analog Devices (ADI) Q3 2025 Earnings Transcript
Image source: The Motley Fool.
Wednesday, August 20, 2025 at 10 a.m. ET
Chairman, President, and Chief Executive Officer — Vincent Roche
Source Fool.com
Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm
Pharmaceutical companies regularly encounter substantial headwinds. Among the most significant are patent cliffs -- when therapies lose patent exclusivity, inviting cheaper generic or biosimilar
2 Dividend Stocks to Buy and Hold
We've seen several investing trends sweep through Wall Street in recent years, from excitement about the cannabis market to the artificial intelligence (AI) industry that's now dominating headlines
AEVIS VICTORIA SA (AEVS.SW) – MRH Switzerland confirms its growth momentum in the first half of 2025 and improves profitability
Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.
President Donald Trump's trade policies have caused tumult on Wall Street. The president has pushed for aggressive tariffs on imported goods in an attempt to bring manufacturing jobs back to the
AEVIS VICTORIA SA – Ordinary General Meeting of Shareholders: all proposals approved
Why Weight-Loss Developer Stocks Tumbled on Tuesday
Makers of weight-loss drugs, the hottest segment of the pharmaceutical market just now, weren't looking so hot on the stock exchange Tuesday. A pronouncement from President Trump about the category
AEVIS VICTORIA SA – Sustained revenue growth in operating divisions. An increase of 17.0% was recorded in the first quarter of 2025.